Laws · international-policy

Himachal Pradesh Licenses Three Pharma Firms for Medicinal Cannabis

The Himachal Pradesh government cleared medicinal cannabis production and issued licences to three pharmaceutical companies, moving the state's program from policy to permitted operations.

By Tomas Greer, State Policy ReporterPublished November 13, 20263 min read
Variety of pills, herbs, and chemical glassware on a white table.

Variety of pills, herbs, and chemical glassware on a white table.

Himachal Pradesh cleared the way for medicinal cannabis production and issued licences to three pharmaceutical companies, according to The News Himachal on Nov. 13, 2026. The move shifts the Indian state's program from enabling policy to licensed operations, though licence terms remain unpublished in available reporting.

Three pharma licences mark the program's first operational step

Himachal Pradesh issued licences to three pharmaceutical companies for medicinal cannabis production, according to The News Himachal. The report, dated Nov. 13, 2026, describes the action as clearing the path for production in the state.

That's a procedural milestone. It isn't a launch.

What the available reporting does not say

The signal doesn't name the licensees, the licensing authority, the governing rule, or the licence terms. Cultivation limits, THC thresholds and permitted end uses go unstated too.

CannIntel hasn't independently reviewed the underlying orders. Those details will decide whether this is a narrow pilot or a scalable framework, and nobody outside the licensing process can say which yet.

The central-law backdrop

India's Narcotic Drugs and Psychotropic Substances Act, 1985, is the federal statute that governs cannabis, and it delegates cultivation rules to the states. Under the NDPS Act, cannabis resin and flowering tops are controlled, while leaves and seeds fall outside the statutory definition. State governments can permit cannabis cultivation for medicinal and scientific purposes under section 10.

Himachal Pradesh is one of several Indian states that have moved on regulated cultivation in recent years. For background on the state's framework, see the CannIntel topic hub on the Himachal Pradesh Medicinal Cannabis Program.

Why licensing pharma firms matters

Restricting early licences to pharmaceutical companies points to a drug-development model rather than an open agricultural market. Pharma licensees typically work under tighter documentation and quality requirements than farmer cooperatives do.

That structure also limits who can take part. Smallholders in hill districts historically tied to illicit cannabis cultivation aren't named as beneficiaries in the report. Whether the rules include a pathway for them is the open question.

Comparison with other Indian states

Uttarakhand and Madhya Pradesh have also pursued regulated medicinal or industrial cannabis programs under their own state rules. Himachal's licences add a third data point for investors and operators tracking whether India's patchwork of state regimes converges.

Federal export and import rules would still apply to any cross-border sales of finished product. On export, the signal says nothing.

What operators should check

The first documents to obtain are the state notification, the licence conditions, and any excise or health department guidelines. They'll show who regulates, how plants are tracked, and what compliance costs look like.

Until then, treat the three-licence figure as the only confirmed fact. Everything about scale and economics is unverified.

What to watch next

The next signals are the published licence conditions and the names of the three licensees. Look for a Himachal Pradesh government notification or excise department order, and for any first-harvest or production timeline from the licensed companies.

Sources

Himachal PradeshIndia medicinal cannabisNDPS Actcannabis licensinginternational cannabis policy
The CannIntel Daily

The cannabis newsletter you forward to your team.

Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.

No spam. Unsubscribe with one click. 21+ only.

Related from Laws

More from the newsroom